ArticleNutrition journal2025
Exploring the impact of coffee consumption and caffeine intake on cognitive performance in older adults: a comprehensive analysis using NHANES data and gene correlation analysis.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuroprotective potential of caffeine in a rotenone-induced Drosophila model of Parkinsonism.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Habitual coffee intake shapes the gut microbiome and modifies host physiology and cognition.Nature communications · 2026Article
- Caffeine May Delay the Radiation-Induced Nucleoshuttling of the ATM Kinase and Reduce the Recognition of the DNA Double-Strand Breaks in Human Cells.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo investigate the effects of coffee consumption and caffeine intake on cognitive performance in older adults, with a particular focus on the potential mediating role of alkaline phosphatase(ALP).
methodsWe analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2014, involving 2,254 participants aged 60 and older. Cognitive performance was assessed using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) test, Animal Fluency test, and Digit Symbol Substitution Test (DSST). To establish causal relationships between coffee consumption, caffeine intake, ALP levels, and cognitive performance, we employed methodologies such as Mendelian randomization, protein quantitative trait locus analysis, and protein-protein interaction networks.
resultsThe NHANES study revealed significant findings regarding coffee consumption and cognitive performance. Compared to non-coffee consumers, individuals consuming ≥ 480 g/day of coffee had a significantly lower odds of low CERAD scores, with an adjusted OR of 0.58 (95% CI: 0.41-0.82) in the fully adjusted Model 4. Similarly, those consuming caffeinated coffee 477.9 g/day) had an OR of 0.56 (95% CI: 0.34-0.92). A comparison of the lowest quartile of ALP intake with the highest quartile showed an OR of 1.82 (95% CI: 1.16-2.85), indicating a negative correlation with cognitive performance. Mendelian Randomization (MR) studies suggested that increased coffee intake is associated with cognitive impairment progression, while coffee consumption may protect against Lewy body dementia (OR = 0.2365, 95% CI: 0.0582-0.9610). Additionally, coffee/caffeine intake affected serum ALP (OR = 0.86, 95% CI: 0.79-0.93) and cognitive ability (OR = 0.95, 95% CI: 0.92-0.98), both indicating protective effects. Finally, the IGFLR1 gene exhibited a moderate colocalization with ALP, suggesting potential therapeutic significance.
conclusionsThis study provides evidence of a positive correlation between coffee consumption, caffeine intake, and cognitive performance in older adults, with ALP potentially contributing to this relationship. These findings underscore the importance of considering dietary factors in cognitive health management for aging populations, highlighting the need for further research to clarify the specific mechanisms involved. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.